Login / Signup

The cost implications of a polypill for primary prevention in the TIPS-3 trial.

Andre LamyWesley TongPhilip JosephPeggy GaoPrem PaisPatricio López-JaramilloMarjan Walli-AttaeiAntonio Miguel DansDenis XavierShamim TalukderAnwar SantosoHabib GamraSalim Yusuf
Published in: European heart journal. Quality of care & clinical outcomes (2022)
The use of a polypill (CES) in TIPS-3 increases costs in lower-middle-income countries and upper-middle-income countries but is affordable in countries at various economic levels and is cost neutral (dominant) in high-income countries.
Keyphrases
  • physical activity
  • mental health
  • clinical trial
  • phase ii
  • open label